To provide articles corresponding to related and other requirements as described below, because a development method for a recombinant influenza vaccine, avoidable of use of helper virus, sufficiently growing up in culture (egg or cell culture), surely enabling development of reconstruction virus proliferatable to develop new vaccine and becoming a means for obtaining systematic mutation for developing an attenuated live virus strain for intranasal vaccine inoculation is required.
An expression plasmid comprising an RNA polymerase I (pol I) promoter and pol I terminator sequences, which are inserted between an RNA polymerase II (pol II) promoter and a polyadenylation signal, is advantageously provided. The expression plasmid is termed herein, a dual promoter expression system or dual promoter expression plasmid. Such a plasmid optimally contains an RNA virus viral gene segment inserted between the pol I promoter and the termination signal. Preferably, the RNA virus is an influenza virus (e.g., an influenza A or influenza B virus).
| JPH11509081A | 1999-08-17 |
JPN6009000130; Ｊ． Ｖｉｒｏｌ． ｖｏｌ．７３， ｎｏ．１１, 1999, ｐ．９６７９-９６８２
JPN5003021743; ＮＥＵＭＡＮＮ ＧＡＢＲＩＥＬＥ: ＰＲＯＣＥＥＤＩＮＧＳ ＯＦ ＴＨＥ ＮＡＴＩＯＮＡＬ ＡＣＡＤＥＭＹ ＯＦ ＳＣＩＥＮＣＥＳ ＯＦ ＴＨＥ ＵＮＩＴＥＤ ＳＴＡＴＥＳ Ｖ９６Ｎ１６, 19990803, Ｐ９３４５-９３５０
JPN5003021741; ＨＯＦＦＭＡＮＮ Ｅ: ＶＩＲＯＬＯＧＹ Ｖ２６７Ｎ２, 20000215, Ｐ３１０-３１７
JPN5003021741; Ｖｉｒｏｌｏｇｙ ｖｏｌ．２６７， ｎｏ．２, 200002, ｐｐ．３１０-３１７
Masatake Shiga
Takashi Watanabe
Shinya Mitsuhiro